8-K

                        UNITED STATES
             SECURITIES AND EXCHANGE COMMISSION
                   WASHINGTON, D.C. 20549


                          FORM 8-K


                       CURRENT REPORT
           PURSUANT TO SECTION 13 OR 15(D) OF THE
               SECURITIES EXCHANGE ACT OF 1934

 Date of Report  (Date of earliest event reported): November 20, 2003


                 Global Life Sciences, Inc.
            ------------------------------------
   (Exact Name of Registrant as Specified in Its Charter)

                         Nevada
                     ---------------
       (State or other jurisdiction of incorporation)


           000-33333                     37-9374101
      --------------------             ----------------
    (Commission File Number)           (I.R.S. Employer
                                      Identification No.)


  2020 Main Street, Suite 600, Irvine, California     92614
 -------------------------------------------------   -------
    (Address of Principal Executive Offices)        (Zip Code)


                       949-223-7103
                  -----------------------
    (Registrant's Telephone Number, including area code)


                     Too Gourmet, Inc.
                 -------------------------
 (Former Name or Former Address, if Changed Since Last Report)






                           - 1 -





Item 5.   Other Events.

We issued a press release on November 20, 2003, in which we
announced the approval by the European Union and the state
of Brandenburg, Germany for a Euro 2.5 million grant (or
approximately $3.0 million) under its EU INTEREG III program
to fund a project to be conducted by the Internationale
Akademie, where Prof. Reimann also serves as its President.
The grant offered by the European Union, will mainly be
utilized to fund the services provided by the company in its
program to develop new and innovative medical techniques in
the field of remote diagnostics technology.  The project
intends to focus on improving diagnostic techniques and
results by enhancing the quality of existing standards and
methods used by physicians during the remote diagnosis
procedure, which could be implemented in future practical
applications.  The grant could be available as early as the
first quarter in calendar 2004 to fund the project.

Item 7.   Financial Statements and Exhibits

a.   Financial Statements

     None.

b.   Pro forma Financial Information

     None.

c.   Exhibits.

99.1 Press Release by Global Life Sciences, Inc., dated
     November 20, 2003, concerning the approval of a Euro
     2.5 million grant (or approximately $3.0 million) to
     the Internationale Akademie, with the company providing
     services thereunder.















                           - 2 -






                         SIGNATURES

     Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly
authorized.

                         GLOBAL LIFE SCIENCES, INC.


November 20, 2003             By:  /s/ Harrysen Mittler
                                 -----------------------
                              Harrysen Mittler
                              Chief Financial Officer































                           - 3 -







Exhibit Index.

99.1 Press Release by Global Life Sciences, Inc., dated
     November 19, 2003, concerning government grants under
     the EU's INTEREG.






































                           - 4 -

EX-99

  GLOBAL LIFE SCIENCES, INC.'S CHAIRMAN RECEIVES GRANT APPROVAL
                     FROM THE EUROPEAN UNION

Irvine, California November 20, 2003:  Global Life Sciences,
Inc., -OTC: GBLS today announced that its Chairman, Prof.
Reimann, has received approval from the European Union and the
state of Brandenburg, Germany for a Euro 2.5 million grant (or
approximately $3.0 million) under its EU INTEREG III program to
fund a project to be conducted by the Internationale Akademie,
where Prof. Reimann also serves as its President.  The research
directed by Prof. Reimann was selected for its outstanding merit
in its category.  The project to be undertaken by Internationale
Akademie will be conducted in cooperation with selected
international universities that may receive an aggregate of
approximately $180,000 of the total grant amount for their
participation.  Please see its website located at
www.Internationale-Akademie.de.

Internationale Akademie, under the guidance of Prof. Reimann, has
selected Global Life Sciences, Inc., as its lead service provider
for the research, analysis, and development of medical procedures
to be implemented by physicians in the field of advanced remote
diagnosis and treatment of individuals suffering from allergic,
immune deficient, and environmentally related disorders at out-
patient clinics and hospitals throughout Europe.  This research
will be conducted at Global Life Sciences, Inc.'s medical
laboratory in Germany.

The grant offered by the European Union, will mainly be utilized
to fund the services provided by Global Life Sciences, Inc., in
its program to develop new and innovative medical techniques in
the field of remote diagnostics technology.  The project intends
to focus on improving diagnostic techniques and results by
enhancing the quality of existing standards and methods used by
physicians during the remote diagnosis procedure, which could be
implemented in future practical applications.  The grant could be
available as early as the first quarter in calendar 2004 to fund
the project.

About Global Life Sciences, Inc.:

Global Life Sciences, Inc., owns and operates a medical
laboratory specializing in the research, analysis, and in vitro
diagnosis of live biopsy tissue samples for allergic,
immunological, and environmentally related disorders.  In order
to improve the quality of test results, Prof. Reimann, the
company's Chairman, Chief Executive Officer, and President,
developed and patented a unique device known as a "Tabox", which
enables the precise analysis of the effects of allergens and
toxins on the human body in an in vitro environment.

Currently, the company operates a total of 28 inter-clinic Tabox
systems as proprietary devices, which are available to
practitioners, clinics and other medical customers on a fee-for-
service basis. The company anticipates the production and use of
up to 100 Tabox systems by its medical customers by the end of
the third quarter 2004. In addition, new labs, research
facilities and integrated out-patient clinics are currently
projected to be established in Zurich (Switzerland) and Berlin
(Germany) during 2004 and 2005.

The Private Securities Litigation Reform Act of 1995 provides a
"safe harbor" for forward-looking statements.  Certain
information included in this press release contains statements
that are forward-looking, such as statements related to the
future anticipated direction of the industry, plans for future
expansion, various business development activities, planned
capital expenditures, future funding sources, anticipated sales
growth, and potential contracts.  Such forward-looking
information involves important risks and uncertainties that could
significantly affect anticipated results in the future and,
accordingly, such results may differ from those expressed in any
forward-looking statements made by, or on behalf of Too Gourmet,
Inc.  These risks and uncertainties include, but are not limited
to, those relating to development and expansion activities,
dependence on existing management, financing activities, and
domestic and global economic conditions.

Investor Contact:
Global Life Sciences, Inc.
Attention:  c/o  R. Katz
Phone:  949-223-7103

Business Contact:
Global Life Sciences, Inc.
Attention:  Prof. Dr. Reimann
Fax:  +49-4503-707532